Drugs / Commercial Influenza vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07291635 Comparator | Feb → Jun 2026 overdue | influenza | Aramis Biotechnologies Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Commercial Influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07291635 ↗ |
| Modality | Vaccine | “Influenza vaccine commercially available on the Canadian market” NCT07291635 ↗ |